BCR-ABL1 WEBINARS

Monitoring CML Patients by RT PCR on the International Scale
Presented by Nick Cross, MA, PhD, FRCPath Professor of Human Genetics at Wessex Regional Genetics Laboratory, U.K

Click here to view this webinar recorded September 26th, 2011
If you are having trouble viewing this video install the gotomeeting video codec found here
Click here to view Dr. Cross's PowerPoint slides

Topics Covered

• Comprehensive coverage of why, when and how IS standardisation was established
• Learn about current approaches to IS Standardisation and their pitfalls
• Understand the development and utilization of WHO reference Standards
• Data review of commercial options for IS Calibration, (ARQ IS Calibrator Panel)
• Considerations for the future, CMR standardisation, enhanced global IS standardisation etc

Current Monitoring for CML: Goals & Principles
Presented by Dr. Jorge Cortes, M.D. Professor of Medicine & Deputy Chair, Dept. of Leukemia, Chief of the CML Section, Dept. of Leukemia at M.D. Anderson Cancer Center in Houston, Texas

Click here to view this webinar recorded July 7th, 2011
If you are having trouble viewing this video install the gotomeeting video codec found here
Click here to view Dr. Cortes's PowerPoint slides

Topics Covered

•Understand current recommendations for monitoring patients with CML
•Discuss the different modalities available for monitoring
•Review the definitions of response
•Discuss the problems with molecular monitoring and how to address them

BCR-ABL1 Quantitation – IS standardization to monitor patients on TKI therapy
Presented by Michael Deininger, M.D., Ph.D. , Huntsman Cancer Institute

Click here to view this webinar recorded May 5th, 2011
Click here to view Dr. Deninger's PowerPoint slides

Webinar Overview

Dr. Michael Deininger working in the lab of Dr. Brian Druker at Oregon Health Science Center, participated in the landmark International Randomised Study of Interferon, IRIS, Clinical Trial in which chronic myeloid leukemia, (CML), patients were treated with Imatinib, establishing the importance of Major Molecular Response (MMR) as a predictor of progression free survival. In this presentation he will give an up to date review of current tyrosine kinase inhibitors, (TKI), therapies for treating CML, including some of the more recent potent TKIs which have been brought to market and are appropriate when Imatinib resistance is encountered. He will describe how BCR-ABL1 fusion transcript levels are measured by q RT PCR to monitor minimal residual disease (MRD) with details regarding the interpretation of these results by the treating physician and the importance of standardizing BCR-ABL1 testing to the International Scale, (IS). He will also draw attention to the BCR-ABL1 test report from the lab and when additional testing is required.

Topics Covered

•Current therapy of chronic myeloid leukemia
•Prognostic implications of Q-PCR results
•International Scale
•Triggers for additional diagnostic measures

Questions from Attendees Answered

Answers


BCR-ABL1 Testing & IS Standardization presented by Dr. Rick Press M.D., Ph.D.

Click here to view this webinar recorded March 31, 2011
If you are having trouble viewing this video install the gotomeeting video codec found here
Click here to view Dr. Press's PowerPoint slides

Webinar Overview

Dr. Rick Press M.D., Ph.D. presents the practical clinical laboratory utilization of BCR-ABL1 quantitative RT-PCR for monitoring the efficacy of tyrosine kinase inhibitor (TKI) therapy in patients with chronic myeloid leukemia (CML). Following the presentation Dr. Press answers questions from the 270 audience members in attendance. Dr. Rick Press is Professor & Director of Molecular Pathology Oregon Health & Science University and is widely regarded as an authority on the topic of BCR-ABL1 testing. He participated in the initial program to establish an International Scale for BCR-ABL1 testing and was a collaborator in the project to make the World Health Organization standards for BCR-ABL1 testing.

Topics Covered

•What lab methods are available for monitoring minimal residual disease in TKI-treated CML?
•What is the goal for monitoring BCR-ABL1 RNA levels during the course of TKI therapy?
•What are the clinically-relevant threshold levels for BCR-ABL1 RNA?
•What is the clinical relevance of rising BCR-ABL1 RNA levels?
•How can BCR-ABL1 RNA levels be standardized between labs?
•What is the international scale for BCR-ABL1 RNA? How can labs convert their assays to the IS?

Questions from Attendees Answered

Answers


Follow @CMLTestingonIS

This website is not funded by or hosted for any advertising source.